Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J R Ballinger

Showing results (21-30 of 82) with videos related to

Pageof 9
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 16, 1998
Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumorsJ R Ballinger, T Muzzammil, M J Moore
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1990
Radiopharmaceutical factors in the variable quality of [99mTc]HM-PAO images of the brainJ R Ballinger, K Y Gulenchyn, R H Reid
International Journal of Cancer|May 18, 1999
Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agentsJ K Tunggal, J R Ballinger, I F Tannock
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1988
Technetium-99m HM-PAO stereoisomers: differences in interaction with glutathioneJ R Ballinger, R H Reid, K Y Gulenchyn
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 1996
In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxiaJ R Ballinger, J W Kee, A M Rauth
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1989
Clinical use of technetium-99m HM-PAO for determination of brain deathR H Reid, K Y Gulenchyn, J R Ballinger
International Journal of Radiation Applications and Instrumentation. Part A, Applied Radiation and Isotopes|January 1, 1989
Technetium-99m spiperone dithiocarbamate: a potential radiopharmaceutical for dopamine receptor imaging with SPECTJ R Ballinger, K Y Gulenchyn, M N Hassan
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|January 1, 1988
Stabilization of stannous pyrophosphate kits with gentisic acidJ R Ballinger, J Pygas, B Gerson, et al.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|August 1, 1992
Evaluation of reduction-mediated labelling of antibodies with technetium-99mZ M Zhang, J R Ballinger, K Sheldon, et al.
Nuclear Medicine and Biology|May 1, 1995
Labelling small quantities of monoclonal antibodies and their F(ab')2 fragments with technetium-99mM Tesic, K M Sheldon, J R Ballinger, et al.
Pageof 9

Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 16, 1998
Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumorsJ R Ballinger, T Muzzammil, M J Moore
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1990
Radiopharmaceutical factors in the variable quality of [99mTc]HM-PAO images of the brainJ R Ballinger, K Y Gulenchyn, R H Reid
International Journal of Cancer|May 18, 1999
Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agentsJ K Tunggal, J R Ballinger, I F Tannock
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1988
Technetium-99m HM-PAO stereoisomers: differences in interaction with glutathioneJ R Ballinger, R H Reid, K Y Gulenchyn
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 1996
In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxiaJ R Ballinger, J W Kee, A M Rauth
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1989
Clinical use of technetium-99m HM-PAO for determination of brain deathR H Reid, K Y Gulenchyn, J R Ballinger
International Journal of Radiation Applications and Instrumentation. Part A, Applied Radiation and Isotopes|January 1, 1989
Technetium-99m spiperone dithiocarbamate: a potential radiopharmaceutical for dopamine receptor imaging with SPECTJ R Ballinger, K Y Gulenchyn, M N Hassan
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|January 1, 1988
Stabilization of stannous pyrophosphate kits with gentisic acidJ R Ballinger, J Pygas, B Gerson, et al.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|August 1, 1992
Evaluation of reduction-mediated labelling of antibodies with technetium-99mZ M Zhang, J R Ballinger, K Sheldon, et al.
Nuclear Medicine and Biology|May 1, 1995
Labelling small quantities of monoclonal antibodies and their F(ab')2 fragments with technetium-99mM Tesic, K M Sheldon, J R Ballinger, et al.
Pageof 9